Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

Yelena Y. Janjigian; Efsevia Vakiani; Geoffrey Y. Ku; Jessica M. Herrera; Laura H. Tang; Nancy Bouvier; Agnès Viale; Nicholas D. Socci; Marinela Capanu; Michael Berger; David H. Ilson

doi:10.1371/journal.pone.0134731

Loading metrics

Open Access

Peer-reviewed

Research Article

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

Yelena Y. Janjigian ,

* E-mail: janjigiy@mskcc.org

Affiliation Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
⨯
Efsevia Vakiani,

Affiliation Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America
⨯
Geoffrey Y. Ku,

Affiliation Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
⨯
Jessica M. Herrera,

Affiliation Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
⨯
Laura H. Tang,

Affiliation Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America
⨯
Nancy Bouvier,

Affiliation Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
⨯
Agnès Viale,

Affiliation Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
⨯
Nicholas D. Socci,

Affiliations Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America, Departments of Bioinformatics, Sloan Kettering Institute, New York, United States of America
⨯
Marinela Capanu,

Affiliation Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States of America
⨯
Michael Berger,

Affiliations Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
⨯
David H. Ilson

Affiliation Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
⨯

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

Yelena Y. Janjigian,
Efsevia Vakiani,
Geoffrey Y. Ku,
Jessica M. Herrera,
Laura H. Tang,
Nancy Bouvier,
Agnès Viale,
Nicholas D. Socci,
Marinela Capanu,
Michael Berger

Published: August 14, 2015
https://doi.org/10.1371/journal.pone.0134731

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Esophageal cancer
Is the Subject Area "Esophageal cancer" applicable to this article?

Thanks for your feedback.
Gastric cancer
Is the Subject Area "Gastric cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Adenocarcinoma
Is the Subject Area "Adenocarcinoma" applicable to this article?

Thanks for your feedback.
Cancer chemotherapy
Is the Subject Area "Cancer chemotherapy" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.